Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers

被引:37
作者
Wilder-Smith, CH
Röhss, K
Nilsson-Pieschl, C
Junghard, O
Nyman, L
机构
[1] Gastroenterol Grp Practice, Gastrointestinal Unit, CH-3011 Bern, Switzerland
[2] Gastrointestinal Physiol Lab, Bern, Switzerland
[3] AstraZeneca R&D, Uppsala, Sweden
[4] Quintiles AB, Uppsala, Sweden
关键词
esomeprazole; lansoprazole; rabeprazole; intragastric acid control; humans; intragastric pH; proton pump inhibitors;
D O I
10.1159/000075697
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers. Methods: In two standardized, randomized crossover studies, Helicobacter pylori negative healthy volunteers (study A: 19 males, 5 females; study B: 13 males, 10 females) received esomeprazole 40 mg and either lansoprazole 30 mg (study A) or rabeprazole 20 mg (study B) orally once daily in the morning for 5 days. Continuous 24-hour intragastric pH recording was performed on day 5. Results: The intragastric pH was maintained >4 for 65% (95% CI 59.5-71.3) of the 24-hour period with esomeprazole and for 53% of the time (95% CI 47.0-58.9) with lansoprazole in study A (p < 0.001). In study B, the proportion of time with pH >4 was 61% (95% CI 53.6-68.3) with esomeprazole versus 45% (95% CI 37.7-52.5) with rabeprazole (p = 0.005). The 24-hour median pH and the proportion of volunteers with intragastric pH 14 for 612 h and 616 h were significantly higher with esomeprazole than with either lansoprazole or rabeprazole. Conclusion: Esomeprazole 40 provides significantly more effective and more sustained gastric acid control than lansoprazole 30 mg or rabeprazole 20 mg in healthy volunteers. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:184 / 188
页数:5
相关论文
共 28 条
[1]  
BELL NJV, 1992, YALE J BIOL MED, V65, P649
[2]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[3]   The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion [J].
Blum, RA ;
Shi, H ;
Karol, MD ;
GreskiRose, PA ;
Hunt, RH .
CLINICAL THERAPEUTICS, 1997, 19 (05) :1013-1023
[4]  
Blum RA, 1998, ALIMENT PHARM THERAP, V12, P321
[5]  
Castell DO, 2002, AM J GASTROENTEROL, V97, P575
[6]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[7]  
Chiba N, 1997, CAN J GASTROENTEROL, V11, P646
[8]   Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects [J].
Hassan-Alin, M ;
Andersson, T ;
Bredberg, E ;
Röhss, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (9-10) :665-670
[10]   Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis [J].
Holloway, RH ;
Dent, J ;
Narielvala, F ;
Mackinnon, AM .
GUT, 1996, 38 (05) :649-654